Matthew Kurian/youtube.com
May 28, 2025, 09:35
Matthew Kurian: Breaking News in mTNBC Treatment – The ASCENT-03 Trial is Redefining First-Line Therapy for mTNBC
Matthew Kurian, Assistant professor of Medicine at the University of Kentucky College of Medicine, shared a post on LinkedIn:
“Breaking News in mTNBC Treatment!
The ASCENT-03 trial is redefining first-line therapy for metastatic triple-negative breast cancer (mTNBC).
Study Design:
Sacituzumab govitecan (Trodelvy) vs. Treatment of Physician’s Choice (TPC)
Participants: Previously untreated, locally advanced, inoperable, or metastatic TNBC patients
Focus: Patients with PD-L1-negative tumors or those previously treated with anti-PD-L1 agents in the early setting
Why It Matters:
Potential to establish Trodelvy as a new first-line standard of care
Addresses unmet needs in a large PD-L1-negative mTNBC patient population
Aims to improve progression-free survival (PFS) and overall survival (OS)
Stay tuned for more updates as results become available in the future!
Look forward to seeing the full data!! 2025 is shaping up to be quite a year for breast cancer advancement!
Great way to lead into ASCO 2025! See you all there!”
More posts featuring Matthew Kurian.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 14:15
May 29, 2025, 13:35
May 29, 2025, 13:11